Heart attack shield? HIV drug combo trial aims to slash plaque
NCT ID NCT07030920
First seen Nov 19, 2025 · Last updated May 22, 2026 · Updated 22 times
Summary
This study tests whether adding a drug called fostemsavir to standard HIV treatment can lower heart disease risk. People with well-controlled HIV and at least one heart risk factor (like smoking or high blood pressure) will get either the extra drug or usual care. Researchers will use heart scans to measure plaque buildup over 24 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR RISK FACTOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CR CHUM
RECRUITINGMontreal, Quebec, H2X 0A9, Canada
Contact
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.